Arrowhead Pharmaceuticals(GB:0HI3)
$42.83-1.96 (-4.38%)
GB:0HI3
Arrowhead Pharmaceuticals financials statements
$42.83
At close:-1.96 (-4.38%)
Arrowhead Pharmaceuticals (0HI3) Financial Statements
0 Followers
Arrowhead Pharmaceuticals Financial Overview
Arrowhead Pharmaceuticals's market cap is currently $6.25B. The company's EPS TTM is $-5.09; its P/E ratio is -8.79; Arrowhead Pharmaceuticals is estimated to report earnings on February 10, 2027, and the estimated EPS forecast is $-1.50. See an overview of income statement, balance sheet, and cash flow financials.
| Sep 26 | Sep 25 | Sep 24 | Sep 23 | Sep 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 450.82M | $ 829.45M | $ 3.55M | $ 240.74M | $ 243.23M |
| Gross Profit | $ 449.02M | $ 829.45M | $ -15.04M | $ 228.24M | $ 232.81M |
| Operating Income | $ -707.17M | $ 98.35M | $ -601.08M | $ -205.00M | $ -178.51M |
| EBITDA | $ -603.59M | $ 164.82M | $ -561.51M | $ -175.67M | $ -162.29M |
| Net Income | $ -724.21M | $ -1.63M | $ -599.49M | $ -205.28M | $ -176.06M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 1.19B | $ 919.37M | $ 680.96M | $ 403.63M | $ 376.40M |
| Total Assets | $ 1.74B | $ 1.39B | $ 1.14B | $ 765.55M | $ 691.94M |
| Total Debt | $ 1.00B | $ 366.28M | $ 851.91M | $ 383.50M | $ 81.58M |
| Net Debt | $ 937.46M | $ 139.74M | $ 749.23M | $ 272.61M | $ -26.43M |
| Total Liabilities | $ 1.69B | $ 881.88M | $ 948.74M | $ 478.39M | $ 273.60M |
| Stockholders' Equity | $ 50.31M | $ 466.05M | $ 185.44M | $ 271.34M | $ 398.52M |
| Cash Flow | |||||
| Free Cash Flow | $ -283.94M | $ 156.89M | $ -604.32M | $ -330.63M | $ -188.91M |
| Operating Cash Flow | $ -271.95M | $ 179.55M | $ -462.85M | $ -153.89M | $ -136.13M |
| Investing Cash Flow | $ -670.48M | $ -129.29M | $ -420.07M | $ -96.16M | $ -5.42M |
| Financing Cash Flow | $ 776.82M | $ 74.01M | $ 870.52M | $ 253.05M | $ 65.19M |
Currency in USD

